MCID: CLR014
MIFTS: 33

Clear Cell Adenoma

Categories: Cancer diseases

Aliases & Classifications for Clear Cell Adenoma

MalaCards integrated aliases for Clear Cell Adenoma:

Name: Clear Cell Adenoma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5390
NCIt 50 C4151
SNOMED-CT 68 1752006
UMLS 73 C0334315

Summaries for Clear Cell Adenoma

Disease Ontology : 12 An adenoma that is composed_of cells with a clear cytoplasm located in ovary.

MalaCards based summary : Clear Cell Adenoma is related to parathyroid transitional clear cell adenoma and water-clear cell adenoma. An important gene associated with Clear Cell Adenoma is PTH (Parathyroid Hormone), and among its related pathways/superpathways are Cushing syndrome and Deactivation of the beta-catenin transactivating complex. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, thyroid and liver, and related phenotypes are cardiovascular system and digestive/alimentary

Related Diseases for Clear Cell Adenoma

Diseases related to Clear Cell Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Related Disease Score Top Affiliating Genes
1 parathyroid transitional clear cell adenoma 34.0 MEN1 PTH
2 water-clear cell adenoma 33.9 PTH TG
3 hyperparathyroidism 30.3 MEN1 PTH PTHLH
4 primary hyperparathyroidism 30.2 MEN1 PTH PTHLH
5 epithelial-myoepithelial carcinoma 11.4
6 adenoma 10.4
7 extraskeletal chondroma 10.2 PTH PTHLH
8 sclerosing hepatic carcinoma 10.2 PTH PTHLH
9 invasive malignant thymoma 10.2 PTH PTHLH
10 hypocalciuric hypercalcemia, familial, type iii 10.2 PTH PTHLH
11 spondylosis 10.2 PTH S100B
12 oncogenic osteomalacia 10.2 PTH PTHLH
13 hypercalcemia, infantile, 1 10.2 PTH PTHLH
14 thyroid gland disease 10.2 PTH TG
15 familial isolated hyperparathyroidism 10.2 MEN1 PTH
16 substernal goiter 10.2 PTH TG
17 cloacogenic carcinoma 10.2 PTH PTHLH
18 endemic goiter 10.2 PTH TG
19 duodenal disease 10.1 MEN1 MUC2
20 papillary adenocarcinoma 10.1 CEACAM5 MUC2
21 thyroid crisis 10.1 PTH TG
22 aggressive digital papillary adenocarcinoma 10.1 CEACAM5 S100B
23 metaphyseal chondrodysplasia, jansen type 10.1 PTH PTHLH
24 functioning pituitary adenoma 10.1 MEN1 S100B
25 duodenum cancer 10.1 MEN1 MUC2
26 nodular hidradenoma 10.1 CEACAM5 KITLG
27 pseudohypoparathyroidism, type ib 10.1 PTH PTHLH
28 pseudohypoparathyroidism 10.1 PTH PTHLH
29 ectopic cushing syndrome 10.1 MEN1 S100B
30 breast adenomyoepithelioma 10.1 CEACAM5 KITLG
31 osteochondroma 10.1 PTHLH S100B
32 breast myoepithelial neoplasm 10.1 CEACAM5 KITLG
33 liver sarcoma 10.1 CEACAM5 PTHLH
34 hypoadrenalism 10.1 PTHLH TG
35 clear cell acanthoma 10.1 CEACAM5 KITLG
36 multiple endocrine neoplasia, type iia 10.1 MEN1 PTH
37 mineral metabolism disease 10.1 PTH PTHLH
38 mast-cell leukemia 10.1 CTNNB1 KITLG
39 islet cell tumor 10.1 MEN1 PTHLH
40 atypical follicular adenoma 10.1 CEACAM5 TG
41 juxtacortical chondroma 10.1 CTNNB1 PTHLH
42 embryonal sarcoma 10.1 CTNNB1 S100B
43 pancreatic cystadenoma 10.1 CEACAM5 MEN1
44 fetal adenoma 10.1 CEACAM5 TG
45 polymorphous low-grade adenocarcinoma 10.1 CTNNB1 S100B
46 parathyroid carcinoma 10.1 MEN1 PTH
47 mucinous intrahepatic cholangiocarcinoma 10.0 MUC2 MUC5AC
48 parathyroid gland disease 10.0 MEN1 PTH PTHLH
49 cap polyposis 10.0 MUC2 MUC5AC
50 parathyroid adenoma 10.0 MEN1 PTH PTHLH

Graphical network of the top 20 diseases related to Clear Cell Adenoma:



Diseases related to Clear Cell Adenoma

Symptoms & Phenotypes for Clear Cell Adenoma

MGI Mouse Phenotypes related to Clear Cell Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 CTNNB1 KITLG MEN1 MUC2 PTH PTHLH
2 digestive/alimentary MP:0005381 9.91 CTNNB1 KITLG MEN1 MUC2 MUC5AC PTHLH
3 homeostasis/metabolism MP:0005376 9.91 CTNNB1 KITLG MEN1 MUC2 MUC5AC PTH
4 endocrine/exocrine gland MP:0005379 9.87 CTNNB1 KITLG MEN1 MUC2 PTH PTHLH
5 craniofacial MP:0005382 9.8 CTNNB1 KITLG MEN1 PTH PTHLH
6 immune system MP:0005387 9.76 CTNNB1 KITLG MEN1 MUC2 MUC5AC PTH
7 limbs/digits/tail MP:0005371 9.35 CTNNB1 KITLG PTH PTHLH TG
8 neoplasm MP:0002006 9.02 CTNNB1 KITLG MEN1 MUC2 PTHLH

Drugs & Therapeutics for Clear Cell Adenoma

Drugs for Clear Cell Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Cisplatin Approved Phase 3,Phase 1 15663-27-1 2767 441203 84093
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Doxil Approved June 1999 Phase 3,Phase 2 31703
7 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
8 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
9 Topoisomerase Inhibitors Phase 3,Phase 2
10 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
12 Antimitotic Agents Phase 3,Phase 2
13
Sunitinib Approved, Investigational Phase 2,Not Applicable 557795-19-4, 341031-54-7 5329102
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
16
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
17
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
18
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
19
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
20
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
21
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
22
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
23
Nintedanib Approved Phase 2 656247-17-5 56843413
24
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
25
Nivolumab Approved Phase 2 946414-94-4
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
28
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
30
Trebananib Investigational Phase 2 894356-79-7
31
Lapatinib Approved March 2007, Investigational Phase 2 388082-78-8, 231277-92-2 208908 9941095
32
Tremelimumab Investigational Phase 2 745013-59-6
33 Calcium, Dietary Phase 2
34 Anticoagulants Phase 2
35 Chelating Agents Phase 2
36 Citrate Phase 2
37 Angiogenesis Inhibitors Phase 2,Not Applicable
38 Angiogenesis Modulating Agents Phase 2,Not Applicable
39 Protein Kinase Inhibitors Phase 2
40 Interleukin-2 Phase 2
41 Analgesics Phase 2
42 Peripheral Nervous System Agents Phase 2
43 Antiviral Agents Phase 2
44 Anti-HIV Agents Phase 2
45 Anti-Retroviral Agents Phase 2
46 Anti-Infective Agents Phase 2,Phase 1
47 Analgesics, Non-Narcotic Phase 2
48 Radiopharmaceuticals Phase 1, Phase 2
49 Fluorodeoxyglucose F18 Phase 1, Phase 2
50 Immunologic Factors Phase 2,Phase 1

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
3 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
4 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
5 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
6 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
7 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
8 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
9 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
10 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
11 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
12 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
13 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
14 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
15 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
16 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
17 Sunitinib in Metastatic Renal Cancer Completed NCT01034878 Phase 2 Sunitinib
18 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
19 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
20 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
21 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
22 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
23 Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Completed NCT00113373 Phase 2 lapatinib ditosylate
24 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
25 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
26 Pembrolizumab and Epacadostat in Treating Participants With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma Recruiting NCT03602586 Phase 2 Epacadostat
27 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
28 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Recruiting NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
29 Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. Recruiting NCT03066427 Phase 2 Sunitinib
30 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
31 A Study of PLX2853 in Advanced Malignancies. Recruiting NCT03297424 Phase 1, Phase 2 PLX2853
32 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
33 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02315430 Phase 2 Cabozantinib S-malate
34 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting NCT02059265 Phase 2 Dasatinib
35 TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00563784 Phase 2 Erlotinib;Carboplatin;Paclitaxel
36 Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Not yet recruiting NCT03348631 Phase 2 Tazemetostat
37 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
38 ATN-161 in Advanced Renal Cell Cancer Terminated NCT00131651 Phase 2 ATN-161
39 ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer Completed NCT00056537 Phase 1 ABR-217620
40 Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery Completed NCT00448643 Phase 1 Cisplatin
41 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting NCT01625351 Phase 1 alemtuzumab;fludarabine;sirolimus;Busulfan;melphalan
42 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Terminated NCT02837991 Phase 1 CDX-014
43 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
44 Ovarian Clear Cell Adenocarcinoma Review Completed NCT02129036
45 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Completed NCT02774395
46 Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy Completed NCT02282579 Pazopanib
47 The Role of Hypoxia as a Selective Pressure for TP53 Mutations Recruiting NCT03466034
48 Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma Active, not recruiting NCT01582204 Not Applicable 124IcG250
49 Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Active, not recruiting NCT01504126 Not Applicable Propranolol;Chemotherapy
50 Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Withdrawn NCT01732432

Search NIH Clinical Center for Clear Cell Adenoma

Genetic Tests for Clear Cell Adenoma

Anatomical Context for Clear Cell Adenoma

MalaCards organs/tissues related to Clear Cell Adenoma:

41
Ovary, Thyroid, Liver, Colon, Breast, Pancreas, Small Intestine

The Foundational Model of Anatomy Ontology organs/tissues related to Clear Cell Adenoma:

19
Ovary

Publications for Clear Cell Adenoma

Articles related to Clear Cell Adenoma:

(show all 15)
# Title Authors Year
1
Water Clear Cell Adenoma of the Parathyroid Gland: A Forgotten Cause of Primary Hyperparathyroidism. ( 28382826 )
2017
2
Water-Clear Cell Adenoma of the Mediastinal Parathyroid Gland. ( 28832084 )
2017
3
Water-clear cell adenoma of parathyroid gland - A case report. ( 27772915 )
2016
4
Water-clear cell adenoma associated with primary hyperparathyroidism: report of a case. ( 23539328 )
2013
5
Water-clear cell adenoma: A rare form of hyperparathyroidism. ( 23995477 )
2013
6
A rare case of primary hyperparathyroidism with clear cell adenoma. ( 15118272 )
2004
7
Clear-cell adenoma of the fallopian tube, a rare tumor of the tubal mucosa. ( 15141314 )
2004
8
Water-clear cell adenoma of the parathyroid gland: a rare entity. ( 15471124 )
2004
9
Thyroid clear cell adenoma with marked dilatation of membranous structures: electron-microscopic study. ( 11758717 )
2001
10
Water-clear cell adenoma of the parathyroid. A case report with immunohistochemistry and electron microscopy. ( 7487410 )
1995
11
Large clear cell adenoma of the parathyroid in a patient with MEN-1 syndrome. Ultrastructural study of the tumour exhibiting unusual RER formations. ( 7725822 )
1994
12
Parotid clear-cell adenoma of possible myoepithelial origin. ( 5075358 )
1972
13
A comparative study of steroid biosyntheses in vitro. In clear cell adenoma and its adjacent tissue of human adrenal gland. ( 4241746 )
1969
14
A comparison of the conversion in vitro of pregnenolone sulphate and pregnenolone to steroid hormones by tissue from a clear cell adenoma of the adrenal gland. ( 5635101 )
1968
15
Corticosteroid synthesis in a clear cell adenoma: a time-based study. ( 4885809 )
1968

Variations for Clear Cell Adenoma

Expression for Clear Cell Adenoma

Search GEO for disease gene expression data for Clear Cell Adenoma.

Pathways for Clear Cell Adenoma

Pathways related to Clear Cell Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.74 CTNNB1 KITLG MEN1
2 10.89 CTNNB1 MEN1
3 10.55 PTH PTHLH
4 9.74 CTNNB1 MEN1

GO Terms for Clear Cell Adenoma

Cellular components related to Clear Cell Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.17 CEACAM5 KITLG MUC5AC PTH PTHLH S100B

Biological processes related to Clear Cell Adenoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.73 CTNNB1 KITLG PTHLH S100B
2 regulation of gene expression GO:0010468 9.65 CTNNB1 PTH PTHLH
3 skeletal system development GO:0001501 9.5 CTNNB1 PTH PTHLH
4 bone mineralization GO:0030282 9.49 PTH PTHLH
5 beta-catenin-TCF complex assembly GO:1904837 9.46 CTNNB1 MEN1
6 regulation of signaling receptor activity GO:0010469 9.46 KITLG PTH PTHLH TG
7 bone resorption GO:0045453 9.4 CTNNB1 PTH
8 osteoblast development GO:0002076 9.37 MEN1 PTHLH
9 regulation of myelination GO:0031641 9.26 CTNNB1 TG
10 cAMP metabolic process GO:0046058 8.96 PTH PTHLH
11 negative regulation of chondrocyte differentiation GO:0032331 8.8 CTNNB1 PTH PTHLH

Molecular functions related to Clear Cell Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 PTH PTHLH TG
2 peptide hormone receptor binding GO:0051428 8.62 PTH PTHLH

Sources for Clear Cell Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....